Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SOD1 | P00441 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1739830 | 0.80 | TEAD1 (0.47) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL9808062 | 0.78 | TEAD1 (0.53) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL10981879 | 0.78 | KMT2A (0.50) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL5974847 | 0.77 | KDM4E (0.49) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL907105 | 0.76 | KMT2A (0.48) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL9546524 | 0.74 | KMT2A (0.47) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL14666345 | 0.74 | KMT2A (0.47) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL1739588 | 0.74 | MAOA (0.42) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL9808024 | 0.74 | KDM4E (0.59) | KMT2AALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL194788 | 0.74 | NR1H2 (0.50) | KMT2AALDH1A1RAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014011540-A1 | BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-01-16 | — | — | WO | claimed |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2440519-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-04-18 | — | — | EP | claimed |
| WO-2010144371-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | claimed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | claimed |
| EP-1879567-A1 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-01-23 | — | — | EP | claimed |
| US-20060247291-A1 | Amino acid derivatives | PFIZER, INC. | 2006-11-02 | — | — | US | claimed |
| WO-2006114707-A1 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | claimed |
| US-4579971-A | HERBICIDES | NIPPON SODA CO. LTD. (JP) | 1986-04-01 | — | — | US | claimed |
| US-4249937-A | 2-(1-ALKYLOXYAMINO-ALKYLIDENE)-5-(ALKYL OR ARYL-SULFENYL, SULFINYL-ALKYL)-1,3-CYCLOHEXADIONE HERBICIDES | NIPPON SODA COMPANY, LTD. (JP) | 1981-02-10 | — | — | US | claimed |
| US-20240239922-A1 | PHOTOCURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240192593-A1 | PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| US-20240191003-A1 | COMPOSITION AND PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| US-11981794-B2 | Curable composition, cured product, and compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-05-14 | — | — | US | disclosed |
| CN-117999296-A | Composition and photosensitive composition | 东京应化工业株式会社 | 2024-05-07 | — | — | CN | disclosed |
| US-4579971-A | HERBICIDES | NIPPON SODA CO. LTD. (JP) | 1986-04-01 | — | — | US | disclosed |
| US-4579971-A | HERBICIDES | NIPPON SODA CO. LTD. (JP) | 1986-04-01 | — | — | US | disclosed |
| US-4177350-A | FUNGICIDES | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1979-12-04 | — | — | US | disclosed |
| US-4154945-A | Fungicidal substituted imidazoles | THE BOOTS COMPANY LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
| US-4080462-A | Fungicidal compositions containing substituted imidazoles | THE BOOTS COMPANY LIMITED (EN) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247291-A1 | Amino acid derivatives | OPRL1, BCAT2, BCAT1 | KMT2A 1916/4885ALDH1A1 1189/4885RAB9A 1647/4885 |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | KMT2A 47/4885ALDH1A1 339/4885RAB9A 3213/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | KMT2A 47/4885ALDH1A1 339/4885RAB9A 3213/4885 |
| US-20240192593-A1 | PHOTOSENSITIVE COMPOSITION | PPOX, ERCC1, ERCC5 | KMT2A 666/4885ALDH1A1 1414/4885RAB9A 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.